Dr. Stephen M. Chang is a distinguished human geneticist with over 32 years of commercial experience in the life sciences, specializing in stem cells, cell and gene therapy, and drug development. He has co-founded multiple companies, including Orpheus Therapeutics, Legacy Therapeutics, Prometheus Therapeutics, and Princeton Drug Discovery, and serves on the boards of Orpheus Therapeutics and Histogen, Inc., where he is also Chairman and Acting CEO. Dr. Chang has held significant roles such as Vice President for Research & Development and Senior Vice President for Strategic Initiatives at the New York Stem Cell Foundation, and Chief Science Officer and Vice President at Canji Inc./Schering Plough Research Institute. His academic background includes a Ph.D. in Biological Chemistry from the University of California, Irvine, and a B.S. in Zoology, Microbiology, and Cell and Molecular Biology from the University of Michigan. Throughout his career, Dr. Chang has co-authored over 30 published papers, filed more than 15 Investigational New Drug Applications with the FDA, and is an inventor on over 50 patents worldwide. He is recognized as a pioneer in commercial gene therapy technologies and induced pluripotent stem cells, with recent successful drug developments including Adstilirin™ (rAd-IFN/Syn3) for bladder cancer therapy and Intravail™ diazepam for epilepsy treatment. Dr. Chang also serves as Entrepreneur in Residence at Rutgers University and New York University, providing strategic guidance on genetic technologies and their market applications.